ITOS iTeos Therapeutics Inc
Price (delayed)
$5.77
Market cap
$220.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.32
Enterprise value
$83.05M
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of
Highlights
ITOS's revenue has surged by 178% year-on-year
iTeos Therapeutics's gross profit has soared by 178% YoY
ITOS's equity is down by 7% from the previous quarter but it is up by 2.6% YoY
The company's net income fell by 19% YoY and by 11% QoQ
The quick ratio is down by 14% QoQ and by 8% YoY
Key stats
What are the main financial stats of ITOS
Market
Valuations
Earnings
Shares outstanding
38.19M
Market cap
$220.38M
Enterprise value
$83.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
6.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.37
Revenue
$35M
Gross profit
$35M
Operating income
-$159.53M
Net income
-$134.41M
EBIT
-$120.34M
EBITDA
-$119.1M
Free cash flow
-$99.81M
Per share
Balance sheet
Liquidity
EPS
-$3.32
EPS diluted
-$3.32
Free cash flow per share
-$2.47
Book value per share
$16.16
Revenue per share
$0.86
TBVPS
$16.97
Total assets
$686.98M
Total liabilities
$96.68M
Debt
$5.1M
Equity
$590.29M
Working capital
$469.18M
Debt to equity
0.01
Current ratio
12.62
Quick ratio
12.28
Net debt/EBITDA
1.15
Margins
Efficiency
Dividend
EBITDA margin
-340.3%
Gross margin
100%
Net margin
-384%
Operating margin
-455.8%
Return on assets
-19.3%
Return on equity
-22.2%
Return on invested capital
-24.1%
Return on capital employed
-18.6%
Return on sales
-343.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITOS stock price
How has the iTeos Therapeutics stock price performed over time
Intraday
2.49%
1 week
-11.23%
1 month
-20.52%
1 year
-54.5%
YTD
-24.87%
QTD
-3.35%
Financial performance
How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$35M
Gross profit
$35M
Operating income
-$159.53M
Net income
-$134.41M
Gross margin
100%
Net margin
-384%
ITOS's revenue has surged by 178% year-on-year
iTeos Therapeutics's gross profit has soared by 178% YoY
The operating margin has soared by 62% YoY but it has decreased by 6% from the previous quarter
iTeos Therapeutics's net margin has surged by 57% YoY but it has decreased by 11% QoQ
Growth
What is iTeos Therapeutics's growth rate over time
Valuation
What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.36
P/S
6.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.37
The EPS has declined by 5% since the previous quarter and by 5% year-on-year
ITOS's P/B is 78% below its 5-year quarterly average of 1.6 and 50% below its last 4 quarters average of 0.7
ITOS's equity is down by 7% from the previous quarter but it is up by 2.6% YoY
ITOS's revenue has surged by 178% year-on-year
Efficiency
How efficient is iTeos Therapeutics business performance
The return on sales has surged by 60% year-on-year but it has declined by 7% since the previous quarter
The ROE has contracted by 21% YoY and by 10% from the previous quarter
The ROA has decreased by 19% YoY and by 10% from the previous quarter
Dividends
What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITOS.
Financial health
How did iTeos Therapeutics financials performed over time
The current ratio has declined by 15% since the previous quarter and by 8% year-on-year
The quick ratio is down by 14% QoQ and by 8% YoY
iTeos Therapeutics's debt is 99% lower than its equity
iTeos Therapeutics's debt has decreased by 16% YoY and by 8% QoQ
ITOS's equity is down by 7% from the previous quarter but it is up by 2.6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.